Mohammad Qadura

MD, PhD

Scientist

Biography

Dr. Mohammad Qadura is a Staff Surgeon in the Division of Vascular Surgery at St. Michael’s Hospital, a Scientist at the Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, and an Assistant Professor at the University of Toronto. Dr. Qadura earned his doctorate in Pathology and Molecular Medicine at Queen’s University.

His interest in personalized medicine has led him to discover novel biomarkers for peripheral arterial disease. Specifically, Dr. Qadura’s research team has conducted in-depth studies to identify miRNA, proteins and metabolites that are strongly associated with peripheral arterial disease. Additionally, Dr. Qadura’s lab also investigates the personalization of anti-platelet and anti-coagulation therapy in patients with atherosclerotic vascular disease.

 Currently accepting graduate students.

Recent Publications

  1. Nguyen, HC, Bu, S, Nikfarjam, S, Rasheed, B, Michels, DCR, Singh, A et al.. Loss of fatty acid binding protein 3 ameliorates lipopolysaccharide-induced inflammation and endothelial dysfunction. J Biol Chem. 2023; :102921. doi: 10.1016/j.jbc.2023.102921. PubMed PMID:36681124 .
  2. Li, B, Djahanpour, N, Zamzam, A, Syed, MH, Jain, S, Arfan, S et al.. The prognostic capability of inflammatory proteins in predicting peripheral artery disease related adverse events. Front Cardiovasc Med. 2022;9 :1073751. doi: 10.3389/fcvm.2022.1073751. PubMed PMID:36582735 PubMed Central PMC9792492.
  3. Zamzam, A, Syed, MH, Rotstein, OD, Eikelboom, J, Klein, DJ, Singh, KK et al.. Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study. EClinicalMedicine. 2023;55 :101766. doi: 10.1016/j.eclinm.2022.101766. PubMed PMID:36531981 PubMed Central PMC9755058.
  4. Feridooni, T, Zamzam, A, Popkov, M, Syed, MH, Djahanpour, N, Wheatcroft, M et al.. Plasma complement component C2: a potential biomarker for predicting abdominal aortic aneurysm related complications. Sci Rep. 2022;12 (1):21252. doi: 10.1038/s41598-022-24698-1. PubMed PMID:36482198 PubMed Central PMC9732295.
  5. Khan, H, Kanny, O, Syed, MH, Qadura, M. Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. Int J Mol Sci. 2022;23 (19):. doi: 10.3390/ijms231911317. PubMed PMID:36232618 PubMed Central PMC9570127.
  6. Li, B, Syed, MH, Khan, H, Singh, KK, Qadura, M. The Role of Fatty Acid Binding Protein 3 in Cardiovascular Diseases. Biomedicines. 2022;10 (9):. doi: 10.3390/biomedicines10092283. PubMed PMID:36140383 PubMed Central PMC9496114.
  7. Khan, H, Popkov, M, Jain, S, Djahanpour, N, Syed, MH, Rand, ML et al.. Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease. Front Cardiovasc Med. 2022;9 :912114. doi: 10.3389/fcvm.2022.912114. PubMed PMID:36035952 PubMed Central PMC9404329.
  8. Li, B, Zamzam, A, Syed, MH, Jahanpour, N, Jain, S, Abdin, R et al.. Urinary Cystatin C Has Prognostic Value in Peripheral Artery Disease. Biomolecules. 2022;12 (7):. doi: 10.3390/biom12070860. PubMed PMID:35883416 PubMed Central PMC9313414.
  9. Li, B, Zamzam, A, Syed, MH, Jahanpour, N, Jain, S, Abdin, R et al.. Urinary Fatty Acid Binding Protein 3 Has Prognostic Value in Peripheral Artery Disease. Front Cardiovasc Med. 2022;9 :875244. doi: 10.3389/fcvm.2022.875244. PubMed PMID:35795372 PubMed Central PMC9250966.
  10. Bu, S, Nguyen, HC, Michels, DCR, Rasheed, B, Nikfarjam, S, Singh, R et al.. Transcriptomics of angiotensin II-induced long noncoding and coding RNAs in endothelial cells. J Hypertens. 2022;40 (7):1303-1313. doi: 10.1097/HJH.0000000000003140. PubMed PMID:35762471 .
Search PubMed

Affiliations & Other Activities

  • Staff Surgeon, Division of Vascular Surgery, St. Michael’s Hospital
  • Associate Professor, University of Toronto